Wyeth India is planning to sell 15 of its tail end products in steroids, hormones and gynec therapeutic ranges, having a combined turnover of Rs 30 crore. A majority of these products belong to the John Wyeth stable, which was merged with Wyeth in the past.

Some of the brands believed to be put on block include Mucaine, Wycort, Ativan, Aludrox, Ossivite, Felban and Ultragin range of brands. The company has already appointed merchant bankers as advisors for the sell off.

Already, the company has identified a buyer for its flagship prednisolone brand Wysolone, it is learnt. Earlier in January, Wyeth sold its cardiac brand Isordil to Mumbai-based IPCA Labs.

Wyeth is in a restructuring mode. The company's plan is to divest its old brands and introduce into market fresh range of innovative products developed by its parent. It is also open to market new products of other MNCs, said the company's management at its AGM.

Over 60 per cent of Wyeth's products are believed to be outsourced from third party manufacturers. Wyeth India has currently two plants at Goa and Valsad. It recently sold its other two units at Ghatkopar and Nasik.

For the nine months ended December 2004, Wyeth India achieved net sales of Rs 218 crore, which is down by 11.5 per cent compared to corresponding previous period's Rs 247 crore. The company realised a net profit of Rs 73.12 crore, which is higher by 44.5 per cent compared to previous corresponding period's Rs 50.60 crore. The higher profits this time is due to sale of Ghatkopar assets of the company worth Rs 33 crore against nil during the corresponding period the previous year.